2-ME, which has been approved by the FDA as an anti-cancer drug, is known to have anti-angiogenic effects and to target HIF-1α [28], and it is used to treat breast, prostate, and ovarian cancer in clinical trials [16,29,30]. Here, HIF1A is linked to ovarian carcinoma.